142 related articles for article (PubMed ID: 19823044)
21. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
22. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
[TBL] [Abstract][Full Text] [Related]
23. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.
Deming DA; Stella AL; Holen KD; Ku G; O'Reilly EM
Clin Adv Hematol Oncol; 2005 Jun; 3(6):468-72; discussion 472-4. PubMed ID: 16167024
[No Abstract] [Full Text] [Related]
24. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.
Ji XQ; Ruan XJ; Chen H; Chen G; Li SY; Yu B
Med Sci Monit; 2011 Aug; 17(8):RA169-176. PubMed ID: 21804474
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
[TBL] [Abstract][Full Text] [Related]
26. Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis.
Senturk H; Canbakan B; Cumali R
J Gastroenterol Hepatol; 2004 Jun; 19(6):719-20. PubMed ID: 15151636
[No Abstract] [Full Text] [Related]
27. The tumour vanishes.
Todd JF; Meeran K
Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
[No Abstract] [Full Text] [Related]
28. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.
Raderer M; Hejna MH; Kurtaran A; Kornek GV; Valencak JB; Oberhuber G; Vorbeck F; Virgolini I; Scheithauer W
Am J Gastroenterol; 1999 Jan; 94(1):278-9. PubMed ID: 9934776
[TBL] [Abstract][Full Text] [Related]
30. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken.
Samonakis DN; Notas G; Christodoulakis N; Kouroumalis EA
Dig Dis Sci; 2008 Sep; 53(9):2359-65. PubMed ID: 18273705
[TBL] [Abstract][Full Text] [Related]
32. Systemic treatment of hepatocellular carcinoma.
Treiber G
Dig Dis; 2001; 19(4):311-23. PubMed ID: 11935091
[TBL] [Abstract][Full Text] [Related]
33. [Complete and sustained remission of liver metastases from neuroendocrine tumor with somatostatin analogue therapy].
Raizer G; Igaz P; Pregun I; Dabasi G; Rácz K
Orv Hetil; 2011 Mar; 152(10):407-10. PubMed ID: 21354958
[TBL] [Abstract][Full Text] [Related]
34. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
[TBL] [Abstract][Full Text] [Related]
35. Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report.
Wang X; Zhou N; Xiao Y; Zhu W; Bai C; Zhao L
Oncologist; 2019 Aug; 24(8):e793-e797. PubMed ID: 31073023
[TBL] [Abstract][Full Text] [Related]
36. [Inhibition effects of octreotide on the growth of hepatocellular carcinoma in vitro and in vivo].
Wang C; Tang C; Tang L
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1194-7. PubMed ID: 11769709
[TBL] [Abstract][Full Text] [Related]
37. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma.
Rabinowitz I; Telepak R; Lee FC
Clin Nucl Med; 2002 Jul; 27(7):499-502. PubMed ID: 12072777
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ
Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186
[TBL] [Abstract][Full Text] [Related]
39. The results of a randomized study on the use of long-acting octreotide in hepatocellular carcinoma.
Borbath I; Horsmans Y
Hepatology; 2003 Feb; 37(2):477-8; author reply 478. PubMed ID: 12575712
[No Abstract] [Full Text] [Related]
40. Somatostatin analogs in acromegaly.
Freda PU
J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
